Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

We examined the effect of glatiramer acetate, a random copolymer of alanine, lysine, glutamic acid, and tyrosine, on antigen-specific T-cell responses in patients with multiple sclerosis (MS). Glatiramer acetate (Copaxone) functioned as a universal antigen, inducing proliferation, independent of any prior exposure to the polymer, in T-cell lines prepared from MS or healthy subjects. However, for most patients, daily injections of glatiramer acetate abolished this T-cell response and promoted the secretion of IL-5 and IL-13, which are characteristic of Th2 cells. The surviving glatiramer acetate-reactive T cells exhibited a greater degree of degeneracy as measured by cross-reactive responses to combinatorial peptide libraries. Thus, it appears that, in some individuals, in vivo administration of glatiramer acetate induces highly cross-reactive T cells that secrete Th2 cytokines. To our knowledge, glatiramer acetate is the first agent that suppresses human autoimmune disease and alters immune function by engaging the T-cell receptor. This compound may be useful in a variety of autoimmune disorders in which immune deviation to a Th2 type of response is desirable.

[1]  D. Hafler.  The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. , 1999, The Journal of clinical investigation.

[2]  M. Sela,et al.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. E. Anderson,et al.  Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis , 1998, Journal of Neuroimmunology.

[4]  J S Wolinsky,et al.  Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability , 1998, Neurology.

[5]  M. Fridkis-Hareli,et al.  Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules , 1997, Journal of immunology.

[6]  M. Sela,et al.  Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Krieger,et al.  Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99. , 1997, Journal of immunology.

[8]  A. Sette,et al.  A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Tonegawa,et al.  Tolerance Induction and Autoimmune Encephalomyelitis Amelioration After Administration of Myelin Basic Protein–derived Peptide , 1997, The Journal of experimental medicine.

[10]  T. Arakawa,et al.  Expression of costimulatory molecules B7-1 and B7-2 in macrophages and granulomas of Crohn's disease: demonstration of cell-to-cell contact with T lymphocytes. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[11]  D. Hafler,et al.  Direct Ex Vivo Analysis of Activated, Fas-sensitive Autoreactive T Cells in Human Autoimmune Disease , 1997, The Journal of experimental medicine.

[12]  Bernhard Hemmer,et al.  Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class II–restricted T Cell Clone , 1997, The Journal of experimental medicine.

[13]  C. Janeway,et al.  Requirement for CD40 Ligand in Costimulation Induction, T Cell Activation, and Experimental Allergic Encephalomyelitis , 1996, Science.

[14]  H. Weiner,et al.  Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. , 1996, The Journal of clinical investigation.

[15]  V. Tuohy,et al.  A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease , 1996, The Journal of experimental medicine.

[16]  M. Sela,et al.  Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses , 1996, Journal of Neuroimmunology.

[17]  D. Hafler,et al.  Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions , 1995, The Journal of experimental medicine.

[18]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[19]  J. Rothbard,et al.  Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. , 1995, Immunity.

[20]  A. Sette,et al.  Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. , 1995, Immunity.

[21]  A. Sette,et al.  Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo , 1995, The Journal of experimental medicine.

[22]  P. Allen,et al.  Significance of T-cell stimulation by altered peptide ligands in T cell biology. , 1995, Current opinion in immunology.

[23]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[24]  D. Mitchell,et al.  Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production , 1994, The Journal of experimental medicine.

[25]  H. Weiner,et al.  Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. , 1994, Science.

[26]  M. Sela,et al.  Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Seidman,et al.  T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice , 1994, The Journal of experimental medicine.

[28]  H. Weiner,et al.  Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis , 1994, The Journal of experimental medicine.

[29]  J. Goverman,et al.  T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. , 1994, Science.

[30]  P. Allen,et al.  Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells , 1993, Nature.

[31]  R. Arnon,et al.  T suppressor hybridomas and interleukin‐2‐dependent lines induced by copolymer 1 or by spinal cord homogenate down‐regulate experimental allergic encephalomyelitis , 1993, European journal of immunology.

[32]  E. Sercarz,et al.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen , 1992, Nature.

[33]  Ursula Esser,et al.  Mapping T-cell receptor–peptide contacts by variant peptide immunization of single-chain transgenics , 1992, Nature.

[34]  P. Allen,et al.  Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. , 1991, Science.

[35]  R J Albertini,et al.  T cells responsive to myelin basic protein in patients with multiple sclerosis. , 1990, Science.

[36]  C. Brosnan,et al.  Immunogenic potentials of copolymer I in normal human lymphocytes , 1985, Neurology.

[37]  R. Arnon,et al.  Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. , 1979, Journal of immunology.

[38]  A. Meshorer,et al.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide , 1971, European journal of immunology.